PACIFIC BIOSCIENCES OF CALIFORNIA INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
PACB$2.36+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (in thousands, except per share amounts) | 2023 | 2022 |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $179,911 | $325,089 |
| Investments | 451,505 | 447,229 |
| Accounts receivable, net | 36,615 | 18,786 |
| Inventory, net | 56,676 | 50,381 |
| Prepaid expenses and other current assets | 17,040 | 10,289 |
| Short-term restricted cash | 300 | 300 |
| Total current assets | 742,047 | 852,074 |
| Property and equipment, net | 36,432 | 41,580 |
| Operating lease right-of-use assets, net | 32,593 | 39,763 |
| Long-term restricted cash | 2,422 | 2,922 |
| Intangible assets, net | 456,984 | 410,245 |
| Goodwill | 462,261 | 409,974 |
| Other long-term assets | 13,274 | 10,528 |
| Total assets | $1,746,013 | $1,767,086 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $15,062 | $12,028 |
| Accrued expenses | 45,708 | 32,596 |
| Deferred revenue, current | 16,342 | 30,498 |
| Operating lease liabilities, current | 9,591 | 8,886 |
| Other liabilities, current | 8,326 | 7,233 |
| Contingent consideration liability, current | — | 172,094 |
| Total current liabilities | 95,029 | 263,335 |
| Deferred revenue, non-current | 5,530 | 1,794 |
| Contingent consideration liability, non-current | 19,550 | — |
| Operating lease liabilities, non-current | 31,606 | 41,070 |
| Convertible senior notes, net, non-current | 892,243 | 896,683 |
| Other liabilities, non-current | 751 | 1,300 |
| Total liabilities | 1,044,709 | 1,204,182 |
| Commitments and contingencies | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value: | ||
| Authorized 50,000 shares; No shares issued or outstanding | — | — |
| Common stock, $0.001 par value: | ||
| Authorized 1,000,000 shares; issued and outstanding 267,744 and 226,505 shares at December 31, 2023 and December 31, 2022, respectively | 268 | 227 |
| Additional paid-in capital | 2,539,892 | 2,099,782 |
| Accumulated other comprehensive income (loss) | 219 | (4,765) |
| Accumulated deficit | (1,839,075) | (1,532,340) |
| Total stockholders’ equity | 701,304 | 562,904 |
| Total liabilities and stockholders’ equity | $1,746,013 | $1,767,086 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.